ROS1 as a 'druggable' receptor tyrosine kinase: lessons learned from inhibiting the ALK pathway (Q38002468)

26 August 2017

ROS1 as a 'druggable' receptor tyrosine kinase: lessons learned from inhibiting the ALK pathway (English)

1 reference

26 August 2017

1 reference

1

Sai-Hong Ignatius Ou

0 references

author name string

Jackie Tan

series ordinal

2

1 reference

PubMed ID

22500682

26 August 2017

Yun Yen

series ordinal

3

1 reference

PubMed ID

22500682

26 August 2017

Ross A Soo

series ordinal

4

1 reference

26 August 2017

1 April 2012

1 reference

Expert Review of Anticancer Therapy

26 August 2017

1 reference

26 August 2017

12

1 reference

26 August 2017

4

1 reference

26 August 2017

447-456

1 reference

Characterization of an activated human ros gene

26 August 2017

1 reference

Characterization of ROS1 cDNA from a human glioblastoma cell line

21 January 2018

1 reference

Fusion of FIG to the receptor tyrosine kinase ROS in a glioblastoma with an interstitial del(6)(q21q21)

21 January 2018

1 reference

Oncogenic kinase signalling

21 January 2018

1 reference

The protein tyrosine kinase family of the human genome

21 January 2018

1 reference

An extracellular beta-propeller module predicted in lipoprotein and scavenger receptors, tyrosine kinases, epidermal growth factor precursor, and extracellular matrix components

21 January 2018

1 reference

The fibronectin type III domain as a scaffold for novel binding proteins

21 January 2018

1 reference

FN3: a new protein scaffold reaches the clinic

21 January 2018

1 reference

The c-ros tyrosine kinase receptor controls regionalization and differentiation of epithelial cells in the epididymis

21 January 2018

1 reference

Sevenless, a cell-specific homeotic gene of Drosophila, encodes a putative transmembrane receptor with a tyrosine kinase domain

21 January 2018

1 reference

The sevenless signaling pathway: variations of a common theme

21 January 2018

1 reference

The little R cell that could

21 January 2018

1 reference

Expression and rearrangement of the ROS1 gene in human glioblastoma cells

21 January 2018

1 reference

Association of a novel PDZ domain-containing peripheral Golgi protein with the Q-SNARE (Q-soluble N-ethylmaleimide-sensitive fusion protein (NSF) attachment protein receptor) protein syntaxin 6

21 January 2018

1 reference

Oncogenic targeting of an activated tyrosine kinase to the Golgi apparatus in a glioblastoma

21 January 2018

1 reference

ROS fusion tyrosine kinase activates a SH2 domain-containing phosphatase-2/phosphatidylinositol 3-kinase/mammalian target of rapamycin signaling axis to form glioblastoma in mice

21 January 2018

1 reference

Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer

21 January 2018

1 reference

The sodium phosphate cotransporter family SLC34

21 January 2018

1 reference

Mutations in the SLC34A2 gene are associated with pulmonary alveolar microlithiasis

21 January 2018

1 reference

CD74: an emerging opportunity as a therapeutic target in cancer and autoimmune disease

21 January 2018

1 reference

Survey of tyrosine kinase signaling reveals ROS kinase fusions in human cholangiocarcinoma

21 January 2018

1 reference

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer

21 January 2018

1 reference

The biology and treatment of EML4-ALK non-small cell lung cancer

21 January 2018

1 reference

Anaplastic lymphoma kinase as a new target for the treatment of non-small-cell lung cancer.

21 January 2018

1 reference

ROS1 rearrangements define a unique molecular class of lung cancers

21 January 2018

1 reference

Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK

21 January 2018

1 reference

Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population

21 January 2018

1 reference

Spectrum of oncogenic driver mutations in lung adenocarcinomas from East Asian never smokers

21 January 2018

1 reference

Mutations of Ros differentially effecting signal transduction pathways leading to cell growth versus transformation

21 January 2018

1 reference

Vav3 mediates receptor protein tyrosine kinase signaling, regulates GTPase activity, modulates cell morphology, and induces cell transformation

21 January 2018

1 reference

Stat3 plays an important role in oncogenic Ros- and insulin-like growth factor I receptor-induced anchorage-independent growth

21 January 2018

1 reference

The role of phosphatidylinositol 3-kinase, rho family GTPases, and STAT3 in Ros-induced cell transformation

21 January 2018

1 reference

Matrix-independent activation of phosphatidylinositol 3-kinase, Stat3, and cyclin A-associated Cdk2 Is essential for anchorage-independent growth of v-Ros-transformed chicken embryo fibroblasts

21 January 2018

1 reference

Negative regulation of Ros receptor tyrosine kinase signaling. An epithelial function of the SH2 domain protein tyrosine phosphatase SHP-1

21 January 2018

1 reference

An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms

21 January 2018

1 reference

Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma

21 January 2018

1 reference

Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors

21 January 2018

1 reference

Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK.

21 January 2018

1 reference

Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK.

21 January 2018

1 reference

EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.

21 January 2018

1 reference

Design, synthesis, screening, and molecular modeling study of a new series of ROS1 receptor tyrosine kinase inhibitors.

21 January 2018

1 reference

Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer

21 January 2018

1 reference

Taming glioblastoma by targeting angiogenesis: 3 years later.

21 January 2018

1 reference

The Hsp90 inhibitor IPI-504 rapidly lowers EML4-ALK levels and induces tumor regression in ALK-driven NSCLC models

21 January 2018

1 reference

RET, ROS1 and ALK fusions in lung cancer

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ERA.12.17

1 reference

26 August 2017

1 reference

PubMed ID

22500682